Idiopathic normal‐pressure hydrocephalus: the cost‐effectiveness of delivering timely and adequate treatment in Germany.

Background and purpose: Idiopathic normal‐pressure hydrocephalus (iNPH) is a progressive, severe brain disorder, which mainly affects people above the age of 65 years. iNPH is characterized by the accumulation of excess cerebrospinal fluid in the brain's ventricles. In most cases, iNPH patients can be effectively treated with shunt surgery, which involves placing a tube into the brain to drain the excess fluid. As part of the European Brain Council‐led Value of Treatment project, this study aimed to investigate the cost‐effectiveness of delivering timely and adequate iNPH treatment in Germany. Methods: The study identified treatment gaps that prevent iNPH patients from receiving adequate and timely treatment. The cost‐effectiveness of delivering shunt surgery to iNPH‐prevalent patients aged ≥65 years in Germany was calculated using decision‐analytical modelling. The model compared two alternatives, current care (shunt surgery in 25% of iNPH cases) and target care (shunt surgery in 90% of iNPH cases), and looked at healthcare costs (diagnosis, shunt intervention and follow‐up care) from the public health insurance perspective, as well as effectiveness outcomes in terms of lives saved and quality‐adjusted life‐years (QALYs) gained. Results: Delivering timely and adequate iNPH treatment proved to be cost‐effective. Cost per life saved varied between €27 921 at 5 years and €246 726 at 15 years. Cost‐per‐QALY estimates varied between €10 202 at 5 years and €35 128 at 15 years. Conclusions: Idiopathic normal‐pressure hydrocephalus is a treatable but often not‐treated disease, resulting in unnecessary and avoidable disease burden for the healthcare system. Actions required to close this treatment gap are straightforward and their implementation has been modelled with successful outcomes. [ABSTRACT FROM AUTHOR]